AngioDynamics, Inc.· ANGO
🇺🇸 US · SmallBroad USNASDAQ
- Price
- $15.19
- Day
- +0.13%
- Mkt Cap
- $627.84M
- 52W Range
- $8.36 – $15.25
- Volume
- 610.8K
- Beta
- 0.34
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.
Read full article
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste
Read full article
AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.
Read full article
ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.
Read full article
AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript
Read full article
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2026, which ended May 31, 2026. Fiscal Year 2026 Fourth Quarter Financial Highlights Quarter Ended May 31, 2026 Pro Forma* YoY Growth Pro Forma* N.
Read full article
AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.
Read full article
AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.
Read full article